Content
Frontiers of Medicine >> 2023, Volume 17, Issue 6 doi: 10.1007/s11684-023-0996-8
BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models
Abstract
Keywords
Content